Wall Street Zen Downgrades Ocugen (NASDAQ:OCGN) to Sell

Ocugen (NASDAQ:OCGN) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other analysts have also commented on the stock. Canaccord Genuity Group lowered their target price on shares of Ocugen from $12.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Weiss Ratings downgraded Ocugen from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.

Ocugen Stock Down 0.8%

Shares of NASDAQ:OCGN opened at $1.27 on Friday. Ocugen has a one year low of $0.96 and a one year high of $2.73. The company has a 50 day moving average of $1.34 and a 200-day moving average of $1.56. The company has a debt-to-equity ratio of 4.17, a current ratio of 0.80 and a quick ratio of 0.80. The stock has a market cap of $430.67 million, a price-to-earnings ratio of -4.88 and a beta of 2.21.

Ocugen (NASDAQ:OCGN) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The company had revenue of $1.49 million for the quarter, compared to analyst estimates of $0.89 million. On average, sell-side analysts forecast that Ocugen will post -0.22 earnings per share for the current year.

Insider Buying and Selling at Ocugen

In other Ocugen news, CFO Treerita Essali Johnson-Greene acquired 21,000 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were acquired at an average price of $1.23 per share, for a total transaction of $25,830.00. Following the acquisition, the chief financial officer directly owned 521,000 shares of the company’s stock, valued at approximately $640,830. This trade represents a 4.20% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.95% of the stock is owned by company insiders.

Institutional Trading of Ocugen

Large investors have recently bought and sold shares of the business. SmartHarvest Portfolios LLC acquired a new stake in Ocugen during the 4th quarter worth approximately $31,000. CTC Alternative Strategies Ltd. acquired a new position in shares of Ocugen in the first quarter valued at approximately $34,000. BNP Paribas Financial Markets boosted its holdings in shares of Ocugen by 56.7% in the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock valued at $36,000 after buying an additional 13,326 shares during the period. NewEdge Advisors LLC boosted its holdings in shares of Ocugen by 198.0% in the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock valued at $36,000 after buying an additional 24,460 shares during the period. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Ocugen during the fourth quarter worth $38,000. 10.27% of the stock is owned by institutional investors.

Ocugen News Summary

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: The FDA cleared Ocugen to begin the Phase 3 OCU410 trial for geographic atrophy associated with dry age-related macular degeneration. The program also received Regenerative Medicine Advanced Therapy designation, potentially enabling priority review and accelerated approval. Ocugen targets three BLAs by 2028
• Positive Sentiment: Ocugen completed a $130 million convertible-notes financing, using roughly $32.7 million to retire higher-cost Avenue Capital debt and extending its expected cash runway into 2028. Cash and restricted cash totaled $100.4 million at June 30. Ocugen second-quarter business update
• Positive Sentiment: The company reported progress across its late-stage pipeline: OCU410 Phase 3 is expected to start this quarter, OCU400 enrollment is complete with topline data expected in the first quarter of 2027, and OCU410ST data are anticipated in the second quarter of 2027. Ocugen Q2 2026 earnings call highlights
• Positive Sentiment: A proposed OCU400 licensing arrangement for the Middle East and North Africa could provide up to $255 million in sales milestones, royalties of 22% on net sales, and an upfront payment. Ocugen reports Q2 results and advances OCU410
• Neutral Sentiment: Second-quarter revenue was $1.49 million, above the $0.89 million analyst estimate, but remains small relative to the company’s development costs. Ocugen reports Q2 loss and beats revenue estimates
• Negative Sentiment: Ocugen’s quarterly loss widened to $0.07 per share from $0.05 a year earlier, missing the $0.05 consensus estimate. Research and development spending rose to $10.7 million, pushing total operating expenses to $17.9 million. Ocugen Q2 earnings miss as R&D costs rise
• Negative Sentiment: The financing improves liquidity but adds convertible debt and potential future share dilution. Ocugen also reported a $24.9 million net loss for the quarter and an accumulated deficit of $452.1 million, underscoring its ongoing dependence on capital markets.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.